期刊文献+

地拉韦啶的合成及晶体结构

Synthesis and Crystal Structure of Delavirdine
下载PDF
导出
摘要 以烟酰胺、对硝基苯肼和丙酮酸乙酯等为原料合成目标化合物地拉韦啶(C23H32N6O4S),并用核磁共振氢谱(1 H NMR)和核磁共振碳谱(13 C NMR)表征其结构,通过X射线单晶衍射确定其晶体结构.实验结果表明:该晶体属于正交晶系,P212121空间群;晶体学数据为:a=1.096 9(4)nm,b=1.152 5(4)nm,c=1.951 0(7)nm,α=90°,β=90°,γ=90°,V=2.468 5(15)nm3,Mr=488.61,Z=4,Dc=1.315g/cm3,λ=0.071 073nm,μ=0.172mm-1,F(000)=1 040,R=0.040 7,wR=0.090 5;共收集14 875个衍射点,其中4 851个为独立衍射点(Rint=0.040 7),在I>2σ(I)时可观察到4 099个衍射点. The title compound delavirdine (C23 H32N6O4S) has been synthesized from nicotinamide,4-nitrophenylhydrazine and ethyl pyruvate. It was characterized by means of 1H NMR and 13C NMR. Its crystal and molecular structures were determined by X-ray diffractometry. It belongs to theorthorhombicsystem, with space group P212121 with a= 1. 096 9(4)nm, b= 1. 152 5(4)nm; c=1.9510(7)nm, α = 90°, β= 90°, γ= 90°, V= 2. 468 5 (15) nm3, Mr= 488. 61, Z= 4,Dc=1.315 g/cm3, ).=0.071 073 nm, μ=0. 172 mm-1, F(000)=1 040, the final R=0. 040 7 and wR=0.090 5. A total of 14 875 reflections were collected, of which 4 851 were independent(Rint=0. 040 7) and 4 099 were observed with γ.
机构地区 吉林大学药学院
出处 《吉林大学学报(理学版)》 CAS CSCD 北大核心 2015年第3期568-571,共4页 Journal of Jilin University:Science Edition
关键词 抗艾滋病药物 地拉韦啶 晶体结构 anti-HIV-1 drug delavirdine crystal structure
  • 相关文献

参考文献8

  • 1Palmer J R,Romero D L,Aristoff P'A,et al. Diaromatic Substituted Compounds as Anti HIV-1 Agents: US,005563142A [P]. 1996-10-08.
  • 2Bergren M S,Chao R S,Meulman P A,et al. Solid Phase of Delavirdine Mesylate [J]. J Pharm Sci, 1996,85(8) : 834-841.
  • 3Havens J L, Smith D P,Bergren M S, et al. Crystal Forms of l-[5-Methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethylamino)~2-pyridinyl] Pioerazine: US, 6452007B1 [P]. 2002-09-17.
  • 4周婷,谢蓝.HIV非核苷类逆转录酶抑制剂研究进展[J].药学学报,2004,38(8):666-672. 被引量:17
  • 5宁兆伦,燕方龙,贺丽鹏,郭岩,王伟,李桂英,王曦,王恩思.新型抗艾滋病药物地拉韦啶的合成[J].吉林大学学报(理学版),2006,44(1):118-122. 被引量:4
  • 6Perrault W R, Shephard K P, LaPean L A, et al. Production Scale Synthesis of the Nonrnucleoside Reverse TranscriptaseInhibitor Atevirdine Mesylate [J], Organic Process Research &- Development, 1997,1(2) : 106-116.
  • 7Romero D L,Morge R A,Biles C,et al. Discovery Synthesis and Bioactivity of Bis (heteroaryl) Piperazinesl. A NovelClass of Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors [J]. J Med Chem, 1994, 37(7) : 999-1014.
  • 8Sheldrick G M. SHELXS 97. Program for the Solution of Crystal Structure [CP], Gottingen. Germany:University of Gottingen, 1997.

二级参考文献43

  • 1Yu H, Kalyan D, Ding JP, et al. Structures of tyr188leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097:inhibitor flexibility is a useful design feature for reducing drug resistance [J]. J Mol Biol, 199
  • 2Parreira RLT, Abrahao O, et al. Conformational preferences of non-nucleoside HIV-1 reverse transcriptase inhibitors [ J ]. Tetrahedron, 2001,57:3243 - 3253.
  • 3Barreca ML, Carotti A, Carrieri A, et al. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs) [ J]. Bioorg Med Chem, 1999,7:2283 -2292.
  • 4Kalyan D, Ding JP, Yu H, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the tyr181cys HIV-1 RT drug-resistant mutant [J]. J Mol Biol, 1996,264:1085- 1100.
  • 5Gonzales M J, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors [J]. AIDS, 2003,17(6):791 -799.
  • 6Wang DP, Rizzo RC, Julian TR, et al. Antiviral drug desigh: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs [ J ].Bioorg Med Chem Lett, 2001,11:2799 -2802.
  • 7Ludovici DW, Kukla M J, Grous PG, et al. Evolution of anti-HIV drug candidates. part 1: from otanilinophenylacetamide (αt-APA) to imidoyl thiourea (ITU) [ J ]. Bioorg Med Chem Lett, 2001,11: 2225 -2228.
  • 8Ludovici DW, Kavash RW, Kukla M J, et al. Evolution of anti-HIV drug candidates. part 2: diaryltriazine (DATA) analogues [J]. Bioorg Med Chem Lett, 2001,11:2229 - 2234.
  • 9Hogberg M, Sahlberg B, Engelhardt P, et al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. synthesis and further structure-activity relationship studies of PETT analogues [ J ]. J Med Chem, 1999,42(20) :4150-4160.
  • 10Esnouf RM, Stuart DI, De Clercq E, et al. Models which explain the inhibition of reverse transcriptase by HIV-1-specific ( thio ) carboxanilide derivatives [ J ].Biochem Biophys Commun, 1997,234(2) :458 -464.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部